Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Semaglutide was tied to nonarteritic anterior ischemic optic neuropathy (NAION) risk vs. nonuse in adults with type 2 diabetes. New semaglutide users did not have higher NAION risk vs. most other ...

Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss. While more research is needed, experts consider semaglutide a promising development in addressing ...

Despite setbacks for projects trying to harness the power of the cytokine interleukin-2 (IL-2) as a cancer therapy, there are still plenty of players on the field – and Roche has just joined ...

Interleukin-2 (IL-2) is a cytokine, a type of immune system signaling molecule, that plays a crucial role in the body's defense against microbial infections and distinguishing between self and non ...